WebAug 6, 2024 · As a result of the close of the transaction announced on Aug. 6, 2024, Medtronic has acquired Intersect ENT's PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility. Intersect ENT employees also join Medtronic through this acquisition. WebSINUVA® Mometasone Furoate 1350 mcg Implant Carton 1 Implant Intersect ENT Inc …
Intersect ENT (XENT) SINUVA Implant Receives FDA Approval
WebMar 8, 2024 · SINUVA is clinically proven to reduce polyps and the need for revision nasal surgery, as well as improve the symptoms of nasal polyps, nasal obstruction, congestion and decreased sense of smell. About Intersect ENT® Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. sterling machinery auctions
CMS Consolidates SINUVA Sinus Implant Coverage Under a …
WebThe NDC Packaged Code 10599-003-01 is assigned to a package of 1 pouch in 1 carton … WebIntersect ENT, a subsidiary of Medtronic, is a health care equipment company based in Menlo Park, California. It manufactures drug-delivery devices used by Ear, Nose & Throat (ENT) clinicians in the treatment of sinusitis.Intersect ENT is best known for developing the first bioabsorbable drug-eluting sinus stent PROPEL, which delivers anti-inflammatory … WebDec 13, 2024 · SINUVA is an exclusive approach to treat recurrent nasal polyp disease in patients who have undergone ethmoid sinus surgery. Per management, approximately 635,000 Americans have gone through these surgeries and are looking for treatments to cure side effects. Intersect ENT expects SINUVA to be costlier than other products in … pirate boy by eve bunting